Rigel Pharmaceuticals, Inc. Profile Avatar - Palmy Investing

Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment o…

Biotechnology
US, South San Francisco [HQ]
Revenue Breakdowns

Segment Analysis Beta

The financial segments are sourced from the SEC' 10-K statement.

Revenue By Top Segments

Rigel Pharmaceuticals, Inc. can't present it's sankey chart.

Historical Revenue By Segment

Last 3Y, in million USD

Rigel Pharmaceuticals, Inc. can't present revenue by segment

Get PRO Today

With PRO you can bypass the blur for the segment revenues of Rigel Pharmaceuticals, Inc..

If you want to see a demo, head over to the financial segments of AAPL

End of RIGL's Analysis
CIK: 1034842 CUSIP: 766559603 ISIN: US7665596034 LEI: - UEI: -
Secondary Listings
RIGL has no secondary listings inside our databases.